Sign In
Buy RHHBY
$54.64
-0.630 (-1.14%)
At Close: Jul 31, 2026
Surface Oncology, Roche Team Up to Develop SRF388 Combo Therapy for Liver Cancer
10:04am, Friday, 04'th Jun 2021
Surface Oncology (NASDAQ: SURF) has entered into a clinical trial collaboration with Roche Holdings AG (OTC: RHHBY) to evaluate former's SRF388, anti-IL-27 antibody, in combination with Roche's a
Roche: Leading Pharmaceutical Company In The Next Decade
10:30am, Thursday, 03'rd Jun 2021
Roche: Leading Pharmaceutical Company In The Next Decade
Roche Is Facing Challenges, But Could Still Be Perfect For Certain Investors
09:34am, Wednesday, 02'nd Jun 2021
Roche is a major, well-known pharmaceutical company based in Basel, Switzerland. The business is under pressure from biosimilars, but I see several reasons to still like the company.
Wide-Moat Stocks On Sale - The June 2021 Heat Map
03:17pm, Wednesday, 26'th May 2021
Our 3-step process focuses on wide-moat stocks (as per Morningstar's rating).
AbbVie-Roche Win European Approval for Venclyxto in Newly Diagnosed Acute Myeloid Leukemia
11:28am, Tuesday, 25'th May 2021
The European Commission has approved AbbVie Inc's (NYSE: ABBV) Venclyxto (venetoclax) for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML). Venclyxto is approved in
Exelixis' Cabometyx, Roche's Tecentriq Combo Achieves 27% ORR in High-Risk Prostate Cancer Patients
07:48am, Tuesday, 25'th May 2021
Exelixis Inc (NASDAQ: EXEL) has announced results from cohort 6 of the COSMIC-021 Phase 1b trial evaluating Cabometyx (cabozantinib) in combination with Roche's Tecentriq (atezolizumab) in pat
With Expenses Growing Faster Than Revenue, Is This Cathie Wood Stock in Trouble?
06:11am, Saturday, 22'nd May 2021
Guardant Health released earnings earlier this month, disappointing investors with its sluggish revenue growth and increasing expenses.
Basel, 20 May 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced interim results from the Phase III IMpower010 study, showing for the first time that treatment with Tecentriq® (atezolizumab)
Analog Devices, Inc. (ADI) CEO Vince Roche on Q2 2021 Results - Earnings Call Transcript
02:54pm, Wednesday, 19'th May 2021
Analog Devices, Inc. (ADI) CEO Vince Roche on Q2 2021 Results - Earnings Call Transcript
Roche's Cobas COVID Test Scores EUA For Asymptomatic People
06:37am, Tuesday, 18'th May 2021
Roche Holdings AG's (OTC: RHHBY) Cobas SARS-CoV-2 Test has received U.S. authorization for testing individuals without symptoms or reasons to suspect a COVID-19 infection. “The high-throughput, h
PLEASANTON, Calif., May 18, 2021 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that its cobas® SARS-CoV-2 Test for use on the widely available, high-throughput cobas® 6800/8800
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that new data from clinical trials of 19 approved and investigational
The 3 Safest Dividend Blue-Chips To Help You Sleep Well At Night
11:09pm, Sunday, 09'th May 2021
The 3 Safest Dividend Blue-Chips To Help You Sleep Well At Night
Basel, 5 May 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Tecentriq® (atezolizumab) as a first-line (initial) treatment for adults with metast
ARK Genomic Revolution ETF: Value Realization Will Take Time
04:46am, Monday, 03'rd May 2021
ARK Genomic Revolution ETF: Value Realization Will Take Time
